摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-(2-nitrophenyl)-1H-pyrrole-3-carboxylate | 1039340-63-0

中文名称
——
中文别名
——
英文名称
methyl 2-(2-nitrophenyl)-1H-pyrrole-3-carboxylate
英文别名
——
methyl 2-(2-nitrophenyl)-1H-pyrrole-3-carboxylate化学式
CAS
1039340-63-0
化学式
C12H10N2O4
mdl
——
分子量
246.222
InChiKey
KZIZYJSEVHNUTK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    492.2±35.0 °C(Predicted)
  • 密度:
    1.347±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    87.9
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    methyl 2-(2-nitrophenyl)-1H-pyrrole-3-carboxylate 在 palladium 10% on activated carbon 、 氢气溶剂黄146(叔丁基亚氨基)三(吡咯烷)膦三氯氧磷 作用下, 以 甲醇二氯甲烷乙腈仲丁醇 为溶剂, 反应 17.0h, 生成
    参考文献:
    名称:
    新型基于1H-吡咯并[3,2-c]喹啉的5-HT受体拮抗剂,可能在治疗与阿尔茨海默氏病相关的认知障碍中具有潜在的应用价值。
    摘要:
    血清素5-HT6受体(5-HT6R)的调节剂为治疗与痴呆和阿尔茨海默氏病相关的认知缺陷提供了一种有前途的策略。在这里,我们报告基于1H-吡咯并[3,2-c]喹啉核心的一类新型的5-HT6R拮抗剂的设计,合成和表征。最具活性的化合物对参考化合物SB-742457表现出可比的结合亲和力,并且选择性显着提高。铅的优化导致对(S)-1-[(3-氯苯基)磺酰基] -4-(吡咯烷-3-基-氨基)-1H-吡咯并[3,2-c]喹啉的鉴定(14)( Ki = 3 nM,Kb = 0.41 nM)。5-HT6R在Gs信号转导上的组成活性的药理学表征表明,14充当中性拮抗剂,而SB-742457被归类为反向激动剂。化合物14和SB-742457均可逆转苯环利定诱发的记忆缺陷,并在NOR任务中在无认知障碍的动物(3 mg / kg)中表现出明显的认知特性。化合物14和SB-742457在Vogel试验中也具有活性,但14的抗焦虑作用高2倍(MED
    DOI:
    10.1021/acschemneuro.6b00090
  • 作为产物:
    参考文献:
    名称:
    闭环复分解在形成2-芳基-1 H-吡咯-3-羧酸盐作为生物活性化合物的基础上的应用
    摘要:
    闭环复分解(RCM)是制备环状有机化合物的有力工具。然而,该方法的主要限制之一是难以制备大量靶分子。在本文中,我们描述了基于相应β-氨基酯的闭环复分解过程作为关键步骤的关于2芳基1 H-吡咯-3-羧酸的克级合成的综合研究。这项研究包括在RCM上评估溶剂和催化剂以及反应动力学。进行芳构化步骤后,此方法可有效生成各种取代的和前所未有的2-芳基-1 H-吡咯-3-羧酸酯具有良好的产率和成本效益。所得的分子可以作为生成面向CNS的化合物库的关键构件。
    DOI:
    10.1016/j.tet.2016.09.059
点击查看最新优质反应信息

文献信息

  • Application of the ring-closing metathesis to the formation of 2-aryl-1H-pyrrole-3-carboxylates as building blocks for biologically active compounds
    作者:Katarzyna Grychowska、Bartłomiej Kubica、Marcin Drop、Evelina Colacino、Xavier Bantreil、Maciej Pawłowski、Jean Martinez、Gilles Subra、Paweł Zajdel、Frédéric Lamaty
    DOI:10.1016/j.tet.2016.09.059
    日期:2016.11
    kinetics on the RCM. After an aromatization step, this methodology allowed for an efficient generation of variously substituted and unprecedented 2-aryl-1H-pyrrole-3-carboxylates in good yields and cost-effectiveness. The resulting molecules might serve as key building blocks for the generation of CNS-oriented compound libraries.
    闭环复分解(RCM)是制备环状有机化合物的有力工具。然而,该方法的主要限制之一是难以制备大量靶分子。在本文中,我们描述了基于相应β-氨基酯的闭环复分解过程作为关键步骤的关于2芳基1 H-吡咯-3-羧酸的克级合成的综合研究。这项研究包括在RCM上评估溶剂和催化剂以及反应动力学。进行芳构化步骤后,此方法可有效生成各种取代的和前所未有的2-芳基-1 H-吡咯-3-羧酸酯具有良好的产率和成本效益。所得的分子可以作为生成面向CNS的化合物库的关键构件。
  • [EN] PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF<br/>[FR] DÉRIVÉS DE PYRROLOQUINOLINE UTILISÉS COMME ANTAGONISTES DE 5-HT6, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION
    申请人:UNIV JAGIELLOŃSKI
    公开号:WO2015012704A1
    公开(公告)日:2015-01-29
    This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.
    这项发明涉及吡咯喹啉衍生物作为5-HT6受体拮抗剂,以及制备这些化合物的方法和用于它们合成的新型中间体。该发明还涉及这些化合物和组合物的用途,特别是它们在向患者施用以达到治疗精神分裂症、焦虑、抑郁症、躁狂抑郁症、癫痫、强迫性障碍、情绪障碍、偏头痛、阿尔茨海默病、年龄相关认知衰退、轻度认知功能障碍、睡眠障碍、进食障碍、厌食症、贪食症、惊恐发作、注意力缺陷多动障碍、注意力缺陷障碍、帕金森病、亨廷顿病、戒除可卡因、乙醇、尼古丁或苯二氮卓类药物滥用、疼痛、肥胖和2型糖尿病、功能性肠道紊乱、肠易激综合征等方面的用途。这些化合物具有一般式(XIV),其中符号的含义如描述中所述。
  • Impact of the Substitution Pattern at the Basic Center and Geometry of the Amine Fragment on 5-HT6 and D3R Affinity in the 1H-Pyrrolo[3,2-c]quinoline Series
    作者:Katarzyna Grychowska、Wojciech Pietruś、Ludmiła Kulawik、Ophélie Bento、Grzegorz Satała、Xavier Bantreil、Frédéric Lamaty、Andrzej J. Bojarski、Joanna Gołębiowska、Agnieszka Nikiforuk、Philippe Marin、Séverine Chaumont-Dubel、Rafał Kurczab、Paweł Zajdel
    DOI:10.3390/molecules28031096
    日期:——
    the substitution pattern at the basic nitrogen atom and the geometry of the amine moiety at position 4 of 1H-pyrrolo[3,2-c]quinoline on the quality of the salt bridge formed in the 5-HT6 receptor and D3 receptor. To reach this goal, we synthetized and biologically evaluated a new series of 1H-pyrrolo[3,2-c]quinoline derivatives modified with various amines. The selected compounds displayed a significantly
    盐桥(SB,双电荷辅助氢键)形成是生物系统中最强的分子非共价相互作用之一,包括配体-受体复合物。在 G 蛋白偶联受体的情况下,这种相互作用是由保守的天冬氨酸 (D3.32) 残基和胺能配体的碱性部分形成的。本研究旨在确定 1H-吡咯并[3,2-c] 喹啉中碱性氮原子的取代模式和胺部分的几何结构对 5- 中形成的盐桥质量的影响。 HT6受体和D3受体。为了实现这一目标,我们合成了一系列新的 1H-吡咯并 [3,2-c] 喹啉衍生物并对其进行了生物学评估,这些衍生物用各种胺进行了修饰。与先前鉴定的化合物 PZ-1643(一种双重作用的 5-HT6R/D3R 拮抗剂)相比,所选化合物显示出显着更高的 5-HT6R 亲和力和更有效的 5-HT6R 拮抗剂特性;然而,拟议的修改并没有改善 D3R 的活动。正如计算机实验(包括分子动力学模拟)所证明的那样,所应用的结构修饰对 5-HT6R 结合位点处 SB
  • Microwave-assisted multi-step synthesis of novel pyrrolo-[3,2-c]quinoline derivatives
    作者:Hafid Benakki、Evelina Colacino、Christophe André、Farhate Guenoun、Jean Martinez、Frédéric Lamaty
    DOI:10.1016/j.tet.2008.04.034
    日期:2008.6
    A new approach for the synthesis of original substituted pyrrolo-[3,2-c]quinoline derivatives using microwave-assisted chemistry is described. The use of microwave activation in this synthesis resulted in high yielding and clean steps. The key step for introducing diversity is the amination or the Pd-catalyzed cross-coupling of an imidoyl chloride derivative, obtained in a straightforward manner and in good yield. (C) 2008 Elsevier Ltd. All rights reserved.
  • Dual 5-HT<sub>6</sub> and D<sub>3</sub> Receptor Antagonists in a Group of 1<i>H</i>-Pyrrolo[3,2-<i>c</i>]quinolines with Neuroprotective and Procognitive Activity
    作者:Katarzyna Grychowska、Severine Chaumont-Dubel、Rafał Kurczab、Paulina Koczurkiewicz、Caroline Deville、Martyna Krawczyk、Wojciech Pietruś、Grzegorz Satała、Szymon Buda、Kamil Piska、Marcin Drop、Xavier Bantreil、Frédéric Lamaty、Elżbieta Pękala、Andrzej J. Bojarski、Piotr Popik、Philippe Marin、Paweł Zajdel
    DOI:10.1021/acschemneuro.8b00618
    日期:2019.7.17
    In light of the multifactorial origin of neurodegenerative disorders and some body of evidence indicating that pharmacological blockade of serotonin 5-HT6 and dopamine D-3 receptors might be beneficial for cognitive decline, we envisioned (S)-1-[(3-chlorophenyl)sulfonyl]-4-(pyrrolidine-3-yl-amino)-1H-pyrrolo[3,2-c]quinoline (CPPQ), a neutral antagonist of 5-HT6R, as a chemical template for designing dual antagonists of 5-HT6/D-3 receptors. As shown by in vitro experiments, supported by quantum chemical calculations and molecular dynamic simulations, introducing alkyl substituents at the pyrrolidine nitrogen of CPPQ, fulfilled structural requirements for simultaneous modulation of 5-HT6 and D-3 receptors. The study identified compound 19 ((S)-1-((3-chlorophenyl)sulfonyl)-N-(1-isobutylpyrrolidin-3-yl)-1H-pyrrolo-[3,2-c] quinolin-4-amine), which was classified as a dual 5-HT6/D3R antagonist (Ki(5-HT6) = 27 nM, K-i(D3) = 7 nM). Compound 19 behaved as a neutral antagonist at G(s) signaling and had no influence on receptor-operated, cyclin-dependent kinase 5 (Cdk5)-dependent neurite growth. In contrast to the well characterized 5-HT6R antagonist intepirdine, compound 19 displayed neuroprotective properties against astrocyte damage induced by doxorubicin, as shown using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) staining to assess cell metabolic activity and lactate dehydrogenase (LDH) release as an index of cell membrane disruption. This feature is of particular importance considering the involvement of loss of homeostatic function of glial cells in the progress of neurodegeneration. Biological results obtained for 19 in in vitro tests, translated into procognitive properties in phencyclidine (PCP)-induced memory decline in the novel object recognition (NOR) task in rats.
查看更多